| Literature DB >> 27883374 |
Hyun Oh Park1, Sung Hwan Kim1, Seong Ho Moon1, Joung Hun Byun1, Jong Woo Kim1, Chung Eun Lee2, Jong Duk Kim2, In Seok Jang2, Jun Ho Yang3.
Abstract
BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) is an important global health problem. Furthermore, the time to identify a positive sputum culture is an important risk factor for the spread of tuberculosis, and several factors can predict a prolonged time to culture conversion. Moreover, the relationship between poor nutritional status and infectious disease is clearly established. Therefore, the present study aimed to investigate the association between body mass index (BMI) and sputum culture conversion within 3 months among patients with MDR-TB.Entities:
Keywords: Multidrug-resistant; Nutritional status; Risk factors; Sputum; Tuberculosis
Year: 2016 PMID: 27883374 PMCID: PMC5204011 DOI: 10.3947/ic.2016.48.4.317
Source DB: PubMed Journal: Infect Chemother ISSN: 1598-8112
Patient characteristics according to body mass index
| All patients No. (%) (n = 218) | BMI of ≥18.5 kg/m2No. (%) (n = 165) | BMI of <18.5 kg/m2No. (%) (n = 53) | ||
|---|---|---|---|---|
| BMI (kg/m2) | 20.0 ± 3.3 | 21.4 ± 2.5 | 15.8 ± 1.5 | |
| Mean age (years) | 41.7 ± 14.2 | 41.4 ± 14.6 | 42.8 ± 12.8 | 0.543 |
| Male sex | 164 (75.2) | 119 (72.1) | 45 (51.1) | 0.069 |
| Previously treated for tuberculosisa | 136 (62.4) | 103 (62.4) | 33(62.3) | 1.000 |
| With cavitation (n = 198)b | 120 (55) | 88 (53.3) | 32 (60.4) | 0.238 |
| Smear positive at the start of treatment | 184 (84.4) | 137 (83) | 47 (88.7) | 0.390 |
| Side effectsc | 82 (37.6) | 62 (37.6) | 20 (37.7) | 1.000 |
| Fluoroquinolone resistanced | 48 (22) | 38 (23) | 10 (18.9) | 0.574 |
| Injectable drug resistancee | 92 (42.2) | 73 (44.2) | 19 (35.8) | 0.338 |
Data are reported as mean ± standard deviation or number (%). Differences were evaluated using the independent samples t-test or Pearson’s chi-square test, as appropriate.
aPatients who denied receiving any anti-tuberculosis treatment or having a >30–day history of anti-tuberculosis treatment.
bChest radiography or computed tomography was performed for all 198 patients.
cSide effects: drug eruption, nausea, vomiting, abdominal discomfort, peripheral neuropathy, nephrotoxicity, hepatic toxicity, ototoxicity, and hypothyroidism.
dIncluded levofloxacin, moxifloxacin, or ofloxacin
eIncluded kanamycin, streptomycin, or amikacin.
BMI, body mass index.
Anti-tuberculosis drugs used for 218 patients with multidrug-resistant tuberculosis
| BMI of ≥18.5 kg/m2No. (%) (n = 165) | BMI of <18.5 kg/m2No. (%) (n = 53) | ||
|---|---|---|---|
| Ethambutol | 19 (11.5) | 9 (17) | 0.346 |
| Pyrazinamide | 72 (43.6) | 28 (52.8) | 0.269 |
| Streptomycin | 81 (49.1) | 31 (58.5) | 0.27 |
| Kanamycin | 85 (51.5) | 22 (41.5) | 0.212 |
| Amikacin | 2 (1.2) | 2 (3.8) | 0.249 |
| Prothionamide | 161 (97.6) | 53 (100) | 0.574 |
| Para-aminosalicylic acid | 132 (80) | 44 (83) | 0.693 |
| Cycloserine | 161 (97.6) | 49 (92.5) | 0.1 |
| Levofloxacin | 86 (52.1) | 26 (49.1) | 0.753 |
| Ofloxacin | 37 (22.4) | 9 (17) | 0.445 |
| Moxifloxacin | 62 (37.6) | 21 (39.6) | 0.871 |
BMI, body mass index
Cox proportional hazards regression analysis of risk factors for sputum culture conversion within 3 months among 218 patients with multidrug-resistant tuberculosis
| Risk factors | Total | Conversionan (%) | Multivariate | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||||
| BMI of <18.5 kg/m2 | 53 | 30 (56.6) | 1.974 (1.191–3.272) | 0.008 | 1.741 (1.006–3.013) | 0.047 |
| Age of ≥40 years | 110 | 74 (67.3) | 1.286 (0.795–2.081) | 0.305 | 1.304 (0.767–2.218) | 0.327 |
| Male sex | 164 | 110 (67.1) | 1.548 (0.843–2.842) | 0.158 | 1.724 (0.878–3.385) | 0.113 |
| Cavitation | 120 | 88 (66.7) | 1.269 (0.737–2.183) | 0.5 | 0.85 (0.481–1.503) | 0.577 |
| Smear positivec | 184 | 118 (64.1) | 11.276 (1.564–81.298) | 0.016 | 8.44 (1.146–62.138) | 0.036 |
| Side effects | 82 | 57 (69.5) | 0.899 (0.547–1.478) | 0.675 | 1.115 (0.642–1.935) | 0.7 |
| FQ resistance | 48 | 30 (62.5) | 1.523 (0.885–2.621) | 0.129 | 1.64 (0.890–3.021) | 0.113 |
| ID resistance | 92 | 60 (65.2) | 1.190 (0.736–1.924) | 0.477 | 1.029 (0.612–1.731) | 0.914 |
aWithin 3 months after the initiation of therapy.
bBoldface indicates a significant difference compared to the baseline characteristics.
cThe sputum smear was positive at the initiation of therapy.
HR, hazard ratio; CI, confidence interval; BMI, body mass index; FQ, fluoroquinolone; ID, injectable drug.
Figure 1Time to initial sputum culture conversion according to body mass index. The time to conversion among patients with a body mass index of <18.5 kg/m2 was significantly longer, compared to the group with a normal body mass index.
BMI, body mass index
The sputum culture conversion results
| BMI of ≥18.5 kg/m2No. (%) | BMI of <18.5 kg/m2No. (%) | |
|---|---|---|
| Achieved SCC | 153 (92.7) | 47 (88.7) |
| Defaulted before achieving SCC | 2 (1.2) | 0 (0) |
| Failed SCC | 9 (5.5) | 4 (7.5) |
| Died before achieving SCC | 1 (0.6) | 2 (3.8) |
| Total | 165 | 53 |
BMI, body mass index; SCC, sputum culture conversion.